Member Info for Kal12

This is an out of the blue, positive catalyst!!! It bridges the gap between their UK listing and their primarily US-based clinical trials (NCT06136884). While OTCQB cross-listings don't guarantee long-term volume, the sudden jump in share price shows that the UK market views this as an excellent shop window for a highly promising precision oncology asset. If u guys agree with me. It is definitely one to watch as they transition into dose-expansion cohorts for prostate and ovarian cancers later this year. We may see let’s of surprises here and let’s hope it’s all positive!!!

Well…looks like Alessandro so busy on the other side of the coin. I hope he remembers those struggling here. What a strange story thou!!!!!

A new all-time high for the Azimut Group, which surpasses €150 billion in total assets.

This achievement is the result of sustained strong momentum. In April, net inflows reached €1.5 billion, bringing the total for the first four months of the year to € 6.1 billion, equal to 61% of the Group’s full year target (€ 10 billion).

Alessandro Zambotti, CEO and CFO of the Group, comments: “This is a powerful confirmation of the strength of our platform, the depth of our client offering and the execution capabilities of our distribution networks and investment professionals across 20 countries. Growth was broad-based across the Group. Italy delivered robust contributions across public and private markets. Abroad, we saw strong demand for our fund solutions in Turkey and another solid print from the USA, which more than offset industry-wide pressure in Brazil linked to volatility in local corporate bond markets, while our strategic affiliates in the US and Australia continued to expand. Surpassing € 150 billion in Total Assets is another important milestone in Azimut’s history and reinforces the strength of our independent, global and diversified business model.”

We look to the future with confidence, determined to turn ambition into tangible value for our clients and investors.

Read the official press release: https://lnkd.in/dGBv76Mv

Jezzaaa- The idea that Lilly 'walked away' is a classic case of forum Chinese whispers:)) it’s just not backed up by the actual regulatory filings. If a Global License Agreement with a $700 billion giant like Eli Lilly were terminated, Hemogenyx would be ((legally)) required to release an RNS immediately, as that is massive 'price-sensitive information.' No such RNS exists. In fact, if you look at the February 10, 2026, and March 31, 2026 updates, the company explicitly states it 'continues to advance its CDX and CBR product candidates' and expects to report progress soon. CDX is the very program Lilly co-developed and licensed to us.

The confusion comes from people mistaking a 'change in roles' for a 'breakup.' Years ago, Lilly was doing the lab work; now, HEMO holds the exclusive license and is the one driving the development while Lilly sits back as the licensor waiting for milestones and royalties. Just because the spotlight is currently on the CAR-T (HG-CT-1) trials doesn't mean the Lilly-linked CDX program has vanished. You don’t see institutional investors dropping £3 million at £8 a share if the company’s biggest partnership had secretly collapsed. They’ve done the due diligence that we can’t see, and they’re buying in at a premium because the 'Lilly Link' is very much alive. I responded with evidence and existing RNS ——Please also respond with evidence ,,,otherwise plz DONT

U see Pumky,,,,the problem you don’t read or understand much. I would suggest that u spend more time reading about what is actually happening rather wasting lots of your time here. Below I will specsome time for you and explain what I meant:

The partnership with Eli Lilly is a formal, legal agreement that’s been in place for a few years now. While HEMO is often associated with its CAR-T program (HG-CT-1), they have a second, very important asset called the CDX bispecific antibody, and that is where Lilly comes in. 

Here is the timeline of how HEMO and Lilly got married,,,,

The Collaboration (Pre-2023): HEMO and Lilly initially worked together under a service agreement. Lilly’s scientists actually carried out a lot of the early work in developing and validating the CDX antibody using their own proprietary tech. 

The Global License Agreement (May 2023): This was the big one. HEMO signed a definitive license agreement with Lilly. Under this deal, Lilly granted HEMO an exclusive worldwide license to the intellectual property needed to develop and commercialize CDX for all uses, including AML. 

The Skin in the Game,,,,to get this deal done, HEMO paid Lilly an upfront fee ($250k) and agreed to milestone payments of up to $1 million through Phase 2, plus substantial royalties and commercial bonuses later on.  

Why this matters for the Kelonia deal:

When the HEMO CEO (who I personally don’t much like) comments on Lilly buying Kelonia, he’s not just an observer,,,he’s commenting on his landlord and business partner. Think of it this way…

Lilly essentially owns a piece of the future success of HEMO’s CDX program. Having Lilly spending $3.25 billion upfront on Kelonia, they are proving they are ready to go "all-in" on the exact same diseases (blood cancers) that HEMO is targeting. It puts HEMO in a very small, elite group of tiny biotechs that already have a direct line into Lilly's oncology department. 

So mate, In short: Lilly didn't just meet HEMO yesterday; they've been in the lab with them for years, and they are now showing the world they have billions of dollars burning a hole in their pocket for this specific type of science. Hope u find this helpful. I really hope so

Hello Saint .. Fair points, and I completely agree,,, but I think we’re looking at two different things. You're looking at the 'old money' share price and I'm looking at the valuation shift.

In 2023, the market treated us like a science experiment that might run out of cash any Tuesday. Today, institutions are writing £3M checks at £8.01. You don't get that kind of buy-in if the 'smart money' thinks you're just a struggling penny stock; they’re buying the future pipeline, not the past chart.

As for the 'sprinting' comment,,,,,I totally get the frustration with the pace of the first three patients. Clinical trials are a grind at the start. But that’s exactly why this RNS matters: you don't raise £3M to keep walking at a snail’s pace. You raise it to build the infrastructure in Estonia and open up the pediatric arm to force the pace. I've been here since the start of the LSE journey with a low average. I’ve seen the 'slow' years. This is the first time the company has had the cash, the partners (Lilly), and the regulatory shortcuts (Estonia) all lined up at once. The first three patients were the 'warm-up' and lets hope the next phase is where the value actually compounds.

When we first got into Hemogenyx, let's be honest: it was a high-risk bet on a small team with a big idea. Back then, we were holding through clinical holds and small, 'hand-to-mouth' raises just to keep the lab lights on. But look at the transformation over the last 12 months. We’ve gone from scraping together £250k chunks in mid-2025 to pulling in £3 million in a single morning from institutional heavyweights at £8.01 a share. That £8.01 figure is the 'receipt'’ for our patience. It proves that the big money now views HEMO as a serious clinical contender, not a penny stock. While the day-traders might squabble over a few pence of volatility today, the reality is that the floor of this company has been permanently raised. Wee are now sitting in a position of strength, watching the 'smart money' chase us at higher prices.

The most important part of this new RNS isn't just the cash but it's the speed. ..accelerating the Phase 1 trials and expanding into kids, management is essentially prepping the company for a 'beauty parade' for Big Pharma. And that Estonia play? It’s a game-changer. It gives HEMO a shortcut to actual commercial use in Europe while the long-term US FDA process plays out. It’s the difference between a company that just 'burns' cash and one that is actively building a bridge to 'earning' it if they make sense.

We’ve seen what Eli Lilly is willing to pay for this kind of tech with the Kelonia deal. By building this war chest now, HEMO isn't just surviving, but they are sprinting.

For those of us who have been here since the beginning, the message is clear: the foundation is built, the funding is secured, and the finish line (whether that's blockbuster data or a massive buyout) is finally within sight. That’s not a recommendation for anyone to buy as there is always risks involved but this is my own perspective. Good luck to u all

Hi am Stonks-,,, I’ve been holding since it was listed in LSE. I’m

Probably one of the oldest holders but not much active here in this chat. I’m also a scientist and somewhat in this research field and I’m not much worried. , and if there’s one thing this sector teaches you, it’s that the 'perfect exit' is a myth. You can’t time these things to the day because value in biotech moves in massive, overnight leaps, not slow climbs. Look at Lilly and Kelonia—that $3.25 billion didn't happen gradually; it was a single handshake that changed the game instantly. My advice? Don’t get obsessed with 'getting out' at a specific moment. We are in the middle of a Phase 1 trial for a reason. If the data is as strong as we expect, a Big Pharma deal won’t give you a 'warning' to buy back in. I’ve averaged £5.30 (up and down) because I’m here for the clinical breakthrough, not just a 10% swing. In two years, we’ll either have the evidence for significant return or we won’t—but jumping out early to try and dodge 'volatility' is how you miss the actual explosion. Stay grounded, watch the data, and remember that we are already in the exact playground where the biggest checks are currently being written. I wish u all the best. Final advice - try to stay away from this board as much as possible unless u a bit bored like me today:) Tim

Regarding those warrants, there hasn't been a brand-new RNS specifically using that term in the last few days, but the timeline of recent filings tells a clear story about what's expiring and what's newly ((in the money.))

Here is the narrative on the warrant situation as of today, April 20, 2026

Most of the noise lately has been about the February 2026 exercises. We saw a batch of warrants converted into roughly 50,000 shares at prices between 180p and 350p. Since the stock has been hovering way higher,,peaking near £10.00 recently,, anybody holding those old, cheap warrants is effectively sitting on a winning lottery ticket. The company puts out "Total Voting Rights" RNS updates every time these are cashed in, which is why you see the share count creeping up to its current 6.43 million total. 

The "big" new block of warrants came from the £2.5 million fundraise back in February. Those investors got warrants with an exercise price of £9.00. Because the share price has been dancing right around that £8.50 to £9.50 range lately, these warrants are "at the money." These don't expire until 2029, so there’s no immediate pressure for those holders to dump them unless they want to cash in on a price spike. 

In short, there’s no "ticking time bomb" expiry RNS that should scare you right now. Instead, the recent warrant activity shows that the early backers are converting their cheap units into full shares because they believe the current price is a floor, not a ceiling. It’s basically a vote of confidence from the people who know the company’s books the best. Hope this helps

The Kelonia deal is a massive neon sign pointing to where the big money is moving, and it puts Hemogenyxx in an incredibly exciting spot. Eli Lilly isn't just dipping their toes in; they are splashing out $3.25 billion in cold, hard cash upfront, with the total deal potential hitting that $7 billion mark as Kelonia hits its milestones. For a company like HEMO, this is huge because it effectively sets the "market price" for early-stage cell therapy. Since HEMO and Lilly already have a working relationship through their CDX licensing deal, CEO comments aren't just polite chatter but they’re a signal that HEMO is operating in the exact same high-value playground that Lilly is currently trying to corner.

When a giant like Lilly pays a multibillion-dollar premium for a Phase 1 asset like Kelonia's, it creates a "rising tide" effect for everyone else in the space. HEMO is pushing forward with its own Phase 1 CAR-T therapy, and the sheer scale of this acquisition suggests that the market has been massively underestimating what these kinds of clinical assets are actually worth to Big Pharma. Essentially, Lilly just told the world that next-gen blood cancer treatments are the industry's "must-have" tech, and HEMO is one of the few independent players left with a seat at that specific table. For shareholders, it turns the conversation from "if" HEMO has value to "how much" a hungry partner might eventually pay to own their pipeline outright. Let’s keep an eye on this very interesting story!!!

Honestly, this linked post isn’t just your CEO sharing random science, it’s more of a subtle strategic message. He’s using this study to show that while in vivo CAR-T sounds revolutionary and very promising, it’s still risky and not fully under control yet. By highlighting that all patients had serious side effects and that the trial was stopped, he is basically saying that the hype is moving faster than the actual clinical reality. At the same time, it helps position him and likely HEMO as thoughtful and grounded rather than just following trends. It also quietly points to a bigger issue in the field, which is safety and lack of control, and suggests that there is still a gap to solve. That can indirectly hint that his company may be taking a more careful or different approach without saying it outright. So overall, the linked post is less about the study itself and more about shaping perception, managing expectations, and subtly differentiating from competitors.!!!hope this helpss

This update from Hemo is actually more important than it looks cuz it shows real behind-the-scenes progress rather than hype. They’ve successfully transferred and validated the manufacturing process for their CAR-T therapy HG-CT-1, meaning it is no longer just a lab concept but something that can be consistently produced under regulatory standards. At the same time, the trial is moving forward with higher doses and expansion into new patient groups, so it is clearly progressing rather than stalling. What stands out is how this compares to many small biotechs that jump from one story to another or rely on headline-driven excitement without building real depth!! HEMO is doing the opposite. It is slowly building the foundation step by step, reducing technical risk, and moving the program forward in a structured way. This kind of progress rarely creates instant share price spikes, but it increases the chances that the science can actually translate into something viable. In simple terms, it is not flashy, but it is real progress, and over time that is what separates companies that survive and eventually re-rate from those that fade away.

Pumpky- Let’s deal with this properly…..

At Admission there will be 425,856,539 shares in issue at 10p, giving a market cap of about £42.6m. That part is correct. To hit a £60m market cap with 425.9m shares, the share price would need to be roughly:

£60m ÷ 425.9m = 14.1p ———Not 17p.

So mathematically, the first £60m trigger would be reached at around 14p, assuming no other share changes. Saying it needs to hit 17p is simply incorrect based on the published share count.

Now the second point.,,,Yes, once £60m market cap is reached, the first 250m deferred shares are activated. But again, that only happens after the company has already risen materially from 10p to roughly 14p. That is about a 40 percent increase from Admission.So the correct framing is that company must first create significant value before the trigger occurs. Again and again, the deferred shares are linked to performance, not activated at today’s level.

Yes Downagain, here is a quick overview:

Wwhat today’s announcement really confirms is that this is no longer the old Roquefort story drifting without direction. This is a full reset into a US focused, clinical stage oncology company built around AO 252, which is already in Phase I and showing early tumour reductions with a benign safety profile. At an anticipated market capitalisation of £42.6 million on admission, the company is being valued as an early clinical biotech with genuine human data emerging, not as a speculative preclinical shell. That positions it more as an execution story than a concept story.

The ownership structure is also a major positive. ((((Nearly half of the shares will not be in public hands)))), and the new leadership team holds very meaningful stakes. The incoming CEO will control over 21 percent, with other senior figures and strategic holders owning substantial positions as well. Directors have committed significant capital into the raise, including £500,000 investments, which is serious money and not symbolic participation. That level of insider ownership and financial commitment creates strong alignment. If the asset succeeds, management wins alongside shareholders. If it fails, they carry material downside too.

On the maths point, yes, the first deferred tranche is linked to a £60 million market capitalisation. But starting from roughly £42.6 million, the company would already need significant appreciation before that level is reached. The deferred shares are performance based and only activate after value creation has occurred. So the issue was never the arithmetic itself, but the way it was framed. The key question remains whether AO 252 can justify valuations above those milestones. If it can, shareholders are already materially up before any deferred shares are triggered.

If we assume the pro forma market cap after the Coiled deal and the £10.5m placing is around £41.5m, then a 50% rise in the share price would take the market cap to roughly £62m. That would move the company past the first £60m hurdle where the initial 250 million deferred shares are triggered. However, those shares only come into play after the company has already grown meaningfully in value. They are performance based and not immediate dilution at today’s level. So the real question is not whether the arithmetic works, it clearly does. The real question is whether the asset can justify a valuation above £60m. If it can, shareholders are already significantly up before that tranche is even activated. Hope this helps

Mate, No one said posting facts is doom. You really need to calm down and read rather than being a single minded person——-Yes, the first 250m deferred shares trigger at a £60m market cap,,,, that’s in the RNS. But that’s not automatic dilution at today’s valuation. It only happens if the company actually reaches that level. Please try to understand this point.

If ROQ hits £60m market cap, that implies material appreciation from current levels. So shareholders would already be up before that tranche even comes into play.

The real question isn’t “are there deferred shares? it’s whether the asset can justify a valuation north of £60m in the first place. Deferred consideration tied to higher market caps is performance-based alignment. It’s not the same as dumping cheap shares into the market tomorrow.

Debate the risk, sure. But let’s frame it correctly. I do remember you from the HEMO chat thou which I have been invested in for more than 7 or 8 years.

Fair point ,,,, the 18 November RNS does show that a large part of the consideration is in shares and that there’s deferred consideration tied to market cap hurdles. That structure absolutely means value won’t crystallise overnight. It’s milestone-based and long-dated.

But that also cuts both ways.

The deferred element only triggers if the company actually hits materially higher market cap levels. In other words, vendors only get the bulk of their upside if shareholders also see significant appreciation. It’s aligned to performance, not guaranteed cash extraction.

Yes, returns could take years,, but that’s normal in oncology biotech. Even a Phase 2 asset can take years before meaningful value inflection. Clinical timelines, not payment structures, are what really determine speed of returns.

So the real debate isn’t “it takes years.”

The debate is: does AO-252 have a realistic path to generating data strong enough to justify those higher valuation thresholds?

If the science works, the deferred consideration becomes almost irrelevant because valuation expands anyway. If the science doesn’t work, even a faster structure wouldn’t save it.

This is a long-horizon biotech bet. The timeline is driven by clinical progress, not just the share mechanics.

That’s actually a fair question and I will answer it without being emotion… It’s a valid comparison, but it’s not that simple.

Yes, on the surface ROQ looks like you’re valuing a largely pre-clinical oncology asset at around £40m, while something like CRTX may appear cheaper on headline market cap and further advanced in human trials. But biotech valuation isn’t just about “what phase is it in”. It’s about, mechanism differentiation, addressable market, competitive setting, safety profile so far, probability-adjusted upside and okwnership and capital structure. A Phase 2 asset at £10m is either massively undervalued or the market sees high risk in the data, cash runway, or prior results. Markets don’t usually miss something that obvious without a reason.

On the ROQ side, the bet isn’t “it’s preclinical so it’s worth £40m today.””” The bet is: if AO-252’s mechanism proves differentiated and shows clean early signals, the upside multiple from a small oncology platform can be significant.

Calling it a “sort your mates out deal” is speculation unless there’s evidence of unfair structuring, lack of lock-ins, or obvious governance abuse. Heavy dilution alone doesn’t equal insider enrichment …. it depends on terms and alignment.

Also, comparing raw market caps without adjusting for cash on balance sheet, Debt, licensing economics, royalty burdens and trail design and endpoints can be misleading. At the end of the day CRTX might be undervalued. ROQ might be early but asymmetric. So both can be risky for different reasons. Biotech is about probability-weighted upside, not just current phase.

Also, as a scientist myself, I forgot to say the most important part her:

The structure is just the vehicle. The paperwork, the market move, the mechanics etc….that’s noise.

The molecule is the bet.

If AO-252 proves it can generate real immune activation and meaningful clinical signals, everything else fades into the background. Valuation will follow data, not corporate reshuffles.In biotech, companies don’t become valuable because of where they’re listed ,,,,they become valuable because a molecule works.

So the deal isn’t the story. The science is the story.

And if the science delivers, the rest takes care of itself.

This RNS can honestly swing both ways. On the negative side, delisting always makes people nervous as it feels like instability, adds uncertainty, and usually comes with dilution hanging over everyone’s head. If the AIM move isn’t seamless or the fundraise comes in below that 1.7p reference level, sentiment could get hit hard and short-term downside could follow. But flip it around, and it could actually be very positive as if the AIM admission lands cleanly, the raise is done at a solid price, and the AO-252 story is positioned well, this becomes a full reset with a clearer biotech focus and potentially fresh specialist investors coming in. So right now it’s not “good” or “bad” — it’s high-risk, high-reward, and the next document basically decides which direction this goes. In the short term could be really stressful but the story may be different for those who can wait. Good luck!

The new RNS is a strong positive development for Hemogenyx. The IRB approval to include pediatric patients in the HG-CT-1 trial expands the therapy’s reach and demonstrates regulatory confidence in its safety profile. It signals encouraging progress from the adult cohort, strengthens the program’s scientific credibility, and opens access to additional regulatory incentives linked to pediatric indications. This move broadens the potential market, enhances partnership appeal, and reinforces Hemogenyx’s position as an emerging innovator in CAR-T for AML. If positive safety and efficacy data continue, the company could see greater investor confidence and a stronger valuation trajectory. Good luck to all investing here